Cited by 1,020Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

NMDA receptor hypofunction model of schizophrenia

Olney, John W, Newcomer, John W, Farber, Nuri B·1999·Journal of Psychiatric Research

DOI 10.1016/s0022-3956(99)00029-1

Open this paper in CoChat — free account

Abstract

Several decades of research attempting to explain schizophrenia in terms of the dopamine hyperactivity hypothesis have produced disappointing results. A new hypothesis focusing on hypofunction of the NMDA glutamate transmitter system is emerging as a potentially more promising concept. In this article, we present a version of the NMDA receptor hypofunction hypothesis that has evolved from our recent studies pertaining to the neurotoxic and psychotomimetic effects of PCP and related NMDA antagonist drugs. In this article, we examine this hypothesis in terms of its strengths and weaknesses, its therapeutic implications and ways in which it can be further tested.

Integrity signals

Registry

Crossref · 10.1016/s0022-3956(99)00029-1

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Excitatory Amino Acid Transmitters
Watkins, J. C., & Evans, R. H. (1981) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.21.040181.001121 · Cited by 2,497
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Self-citation
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Self-citation
Ketamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,230
Self-citation
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921

Show all 63 references

Research works printed but not linked: 7

Anand, 1997, Reduction in ketamine effects in humans by lamotrigine, Society for Neuroscience Abstracts, 23, 1755
Farber, 1997, Costimulation of muscarinic and nonNMDA glutamate receptors reproduces NMDA antagonist neurotoxicity, Society for Neuroscience Abstracts, 23, 2308
Newcomer, 1998, Guanabenz effects on NMDA antagonist-induced mental symptoms in humans, Society for Neuroscience Abstracts, 24, 525
Newcomer JW, Selke G, Melson A, White DA, Roediger HL, Farber NB, Wozniak DF, Jevtovic-Todorovic V, Olney JW. NMDA antagonist-induced decreases in working and explicit memory in humans. Society for Neuroscience Abstracts 1999b;25 (in press).
Olney, 1998, Alcohol induces massive apoptotic neurodegeneration in the developing rat CNS, Society for Neuroscience Abstracts, 24, 1983
Olney JW, Wozniak DF, Price MT, Tenkova TI, Dikranian K, Ikonomidou C. Ethanol induces widespread apoptotic neurodegeneration in the infant mouse brain. Society for Neuroscience Abstracts 1999;25 (in press).
Price MT, Wozniak DF, Tenkova TI, Dikranian K, Ikonomidou C, Olney JW. Ethanol induces widespread apoptotic neurodegeneration in the fetal guinea pig brain. Society for Neuroscience Abstracts 1999;25 (in press).

Sorted by citations

Items 301–400 of 999

Cerebral metabolic patterns in chronic and recent-onset schizophrenia
Desco, M., Gispert, J. D., Reig, S., Sanz, J., Pascau, J., Sarramea, F., Carlos Benito, C., Santos, A., Palomo, T., & Molina, V. (2003) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(02)00124-5 · Cited by 56
Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice
Jeevakumar, V., & Kroener, S. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhu293 · Cited by 59
Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways
Kim, J., & Monteggia, L. M. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112378 · Cited by 56
Impaired Limbic Cortico-Striatal Structure and Sustained Visual Attention in a Rodent Model of Schizophrenia
Barnes, S. A., Sawiak, S. J., Caprioli, D., Jupp, B., Buonincontri, G., Mar, A. C., Harte, M., Fletcher, P. C., Robbins, T. W., Neill, J. C., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu010 · Cited by 55
N-Methyl-D-Aspartate Receptor and Calbindin-Containing Neurons in the Anterior Cingulate Cortex in Schizophrenia and Bipolar Disorder
Woo, T.-U. W., Shrestha, K., Lamb, D., Minns, M., & Benes, F. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.034 · Cited by 54
Increased hippocampal blood volume and normal blood flow in schizophrenia
Talati, P., Levendovszky, S. R., Skinner, J. T., Gore, J. C., & Heckers, S. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.03.007 · Cited by 51
Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia
Jelen, L. A., King, S., Mullins, P. G., & Stone, J. M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117747579 · Cited by 54
d-Alanine: Distribution, origin, physiological relevance, and implications in disease
Lee, C. J., Qiu, T. A., & Sweedler, J. V. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140482 · Cited by 56
SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function
Bae, M. H., Roh, J. D., Kim, Y.-J., Kim, S. S., Han, H. M., Yang, E., Kang, H., Lee, S., Kim, J. Y., Kang, R., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012632 · Cited by 54
The therapeutic potential of glycine transporter-1 inhibitors
Sur, C., & Kinney, G. G. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.5.515 · Cited by 54
The neuroanatomy of schizophrenia: circuitry and neurotransmitter systems
Fallon, J. H., Opole, I. O., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00022-7 · Cited by 53
Association of SNPs in EGR3 and ARC with Schizophrenia Supports a Biological Pathway for Schizophrenia Risk
Huentelman, M. J., Muppana, L., Corneveaux, J. J., Dinu, V., Pruzin, J. J., Reiman, R., Borish, C. N., De Both, M., Ahmed, A., Todorov, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135076 · Cited by 52
“EGR3 is regulated downstream of several key schizophrenia candidate proteins, including Neuregulin 1, N-methyl D-Aspartate Receptors (NMDARs) and calcineurin (CN) [11, 16–21], and Egr3KOmice share key phenotypes with NMDARKO and CNKO mice, including memory dysfunction and deficits in the form of hippocampal synaptic p…”
Background
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases
Li, S. H., Abd‐Elrahman, K. S., & Ferguson, S. S. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108275 · Cited by 53
The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment
Iasevoli, F., Tomasetti, C., Buonaguro, E. F., & de Bartolomeis, A. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140324183406 · Cited by 53
Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain
Stojković, T., Radonjić, N. V., Velimirović, M., Jevtić, G., POPOVIC, V. M., Doknić, M., & Petronijević, N. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.013 · Cited by 53
Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-D-aspartate currents by dopamine D1 receptor activation in striatum
Jocoy, E. L. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00028 · Cited by 54
Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study
Gemperle, A. Y., Enz, A., Pozza, M. F., L�thi, A., & Olpe, H. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00769-8 · Cited by 54
Dissection of brain-wide resting-state and functional somatosensory circuits by fMRI with optogenetic silencing
Jung, W. B., Jiang, H., Lee, S., & Kim, S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113313119 · Cited by 53
Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: Evidence from genetically modified mouse models and pharmacological inhibition
Möhler, H., Boison, D., Singer, P., Feldon, J., Pauly-Evers, M., & Yee, B. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.003 · Cited by 52
Glutamate receptors in domestication and modern human evolution
O’Rourke, T., & Boeckx, C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.004 · Cited by 50
Anti-NMDA-Rezeptor-Enzephalitis
Prüß, H., Dalmau, J. O., Arolt, V., & Wandinger, K.-P. (2010) · Der Nervenarzt · doi:10.1007/s00115-009-2908-9 · Cited by 48
Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding
Palmer, A. A., Brown, A. S., Keegan, D. A., Siska, L. D., Susser, E., Rotrosen, J., & Butler, P. D. (2008) · Brain Research · doi:10.1016/j.brainres.2008.07.089 · Cited by 51
Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome
Alves, F. D. S., Boot, E., Schmitz, N., Nederveen, A. J., Vorstman, J. A. S., Lavini, C., Pouwels, P. J. W., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021685 · Cited by 50
Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats
Tascedda, F., Blom, J. M. C., Brunello, N., Zolin, K., Gennarelli, M., Colzi, A., Bravi, D., Carra, S., Racagni, G., & Riva, M. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01135-0 · Cited by 51
Role of the medial prefrontal cortex in N-methyl-d-aspartate receptor antagonist induced sensorimotor gating deficit in rats
Schwabe, K., & Koch, M. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.10.028 · Cited by 51
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia
Koh, M. T., Shao, Y., Sherwood, A., & Smith, D. R. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.023 · Cited by 51
Glutamate-based therapeutic approaches: inhibitors of glycine transport
Lechner, S. M. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.002 · Cited by 50
Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat
Jenkins, T. A., Harte, M., McKibben, C. E., Elliott, J. J., & Reynolds, G. P. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.07.020 · Cited by 50
The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Egerton, A., & Stone, J. M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 51
Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs
Bespalov, A., Jongen-Rêlo, A.-L., van Gaalen, M. M., Harich, S., Schoemaker, H., & Groß, G. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110684 · Cited by 49
Metabotropic Glutamate Receptors in Central Nervous System Diseases
Golubeva, A. V., Moloney, R. D., O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2016) · Current Drug Targets · doi:10.2174/1389450116666150316224011 · Cited by 51
Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A/2C receptors
Su, Y., Si, T., Zhou, D., Guo, C., Wang, X., Yang, Y., Shu, L., & Liang, J. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.031 · Cited by 49
Semantic Priming after Ketamine Acutely in Healthy Volunteers and Following Chronic Self-Administration in Substance Users
Morgan, C. J. A., Rossell, S. L., Pepper, F., Smart, J., Blackburn, J., Brandner, B., & Curran, H. V. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.018 · Cited by 49
Long-Lasting Impairment of Associative Learning Is Correlated with a Dysfunction of N-Methyl-d-aspartate-Extracellular Signaling-Regulated Kinase Signaling in Mice after Withdrawal from Repeated Administration of Phencyclidine
Enomoto, T., Noda, Y., Mouri, A., Shin, E., Wang, D., Murai, R., Hotta, K., Furukawa, H., Nitta, A., Kim, H., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011304 · Cited by 49
Glutamate Receptor Genes
Schiffer, H. H. (2002) · Molecular Neurobiology · doi:10.1385/mn:25:2:191 · Cited by 49
Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia
Geddes, A. E., Huang, X., & Newell, K. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.017 · Cited by 52
The Ampakine CX546 Restores the Prepulse Inhibition and Latent Inhibition Deficits in mGluR5-Deficient Mice
Lipina, T. V., Weiss, K. C., & Roder, J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301191 · Cited by 48
The Role of Caspase-3 Activation in Phencyclidine-Induced Neuronal Death in Postnatal Rats
Wang, C. Z., & Johnson, K. M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301202 · Cited by 48
Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors
Javitt, D., Hashim, A., & Sershen, H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300589 · Cited by 48
Glial transporters for glutamate, glycine, and GABA III. Glycine transporters
Gadea, A., & López-Colomé, A. M. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1069 · Cited by 48
Brain iron assessment in patients with First-episode schizophrenia using quantitative susceptibility mapping
Xu, M. K., Guo, Y., Cheng, J., Xue, K., Yang, M., Song, X., Feng, Y., & Cheng, J. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102736 · Cited by 47
Signaling molecules and receptor transduction cascades that regulate nmda receptor-mediated synaptic transmission
Kotecha, S. A., & MacDonald, J. F. (2003) · International review of neurobiology · doi:10.1016/s0074-7742(03)54003-x · Cited by 47
The possible involvement of metabotropic glutamate receptors in schizophrenia
Krivoy, A., Fischel, T., & Weizman, A. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.11.001 · Cited by 47
How Nox2-Containing NADPH Oxidase Affects Cortical Circuits in the NMDA Receptor Antagonist Model of Schizophrenia
Wang, X., Pinto-Duarte, A., Sejnowski, T. J., & Behrens, M. M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4907 · Cited by 46
Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant
Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46
Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain
Lauriat, T. L., Dracheva, S. M., Chin, B., Schmeidler, J., McInnes, L. A., & Haroutunian, V. H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.003 · Cited by 46
Association between SNPs and gene expression in multiple regions of the human brain
Kim, S. Y., Cho, H., Lee, D., & Webster, M. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.42 · Cited by 46
Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE
Özyurt, B., Özyurt, H., Akpolat, N., Erdoğan, H., & Sarsılmaz, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.01.029 · Cited by 46
Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: Relevance to animal models of antipsychotic drugs
Sun, T., Hu, G., & Li, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.11.036 · Cited by 45
Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study
Lee, J. G., Lee, S. W., Lee, B. J., Park, S. W., Kim, G. M., & Kim, Y. H. (2012) · Psychiatry Investigation · doi:10.4306/pi.2012.9.2.166 · Cited by 46
Targeting Neural Synchrony Deficits is Sufficient to Improve Cognition in a Schizophrenia-Related Neurodevelopmental Model
Lee, H., Dvořák, D., & Fenton, A. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00015 · Cited by 45
Dopamine receptor subtypes contribution to Homer1a induction: Insights into antipsychotic molecular action
Iasevoli, F., Tomasetti, C., Ambesi‐Impiombato, A., Muscettola, G., & de Bartolomeis, A. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.02.009 · Cited by 45
COX-2 Inhibitors as Adjunctive Therapy in Schizophrenia
Riedel, M. J., Strassnig, M., Schwarz, M., & ller, N. M. ⁄. (2005) · CNS Drugs · doi:10.2165/00023210-200519100-00001 · Cited by 45
Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients
Smesny, S., Gussew, A., Biesel, N. J., Schack, S., Walther, M., Rzanny, R., Milleit, B., Christian Gaser, B., Sobanski, T., Schultz, C. C., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.013 · Cited by 44
Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat
McLean, S. L., Neill, J. C., Idris, N. F., Marston, H. M., Wong, E. H. F., & Shahid, M. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.043 · Cited by 44
Neurodegeneration in Schizophrenia: Evidence fromIn VivoNeuroimaging Studies
Csernansky, J. G. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.47 · Cited by 44
Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism
Bridges, T. M., Rook, J. M., Noetzel, M. J., Morrison, R. D., Zhou, Y., Gogliotti, R. D., Vinson, P. N., Xiang, Z., Jones, C. K., Niswender, C. M., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052084 · Cited by 44
NMDA receptor-dependent function and plasticity in inhibitory circuits
Moreau, A. W., & Kullmann, D. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.004 · Cited by 44
Is elevated norepinephrine an etiological factor in some cases of schizophrenia?
Fitzgerald, P. J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.011 · Cited by 44
Mouse strain differences in phencyclidine-induced behavioural changes
Mouri, A., Koseki, T., Narusawa, S., Niwa, M., Mamiya, T., Kano, S., Sawa, A., & Nabeshima, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100085x · Cited by 44
Prenatal inflammation and risk for schizophrenia: A role for immune proteins in neurodevelopment
Allswede, D. M., & Cannon, T. D. (2018) · Development and Psychopathology · doi:10.1017/s0954579418000317 · Cited by 46
Design, Synthesis, and In Vivo Efficacy of Glycine Transporter‐1 (GlyT1) Inhibitors Derived from a Series of [4‐Phenyl‐1‐(propylsulfonyl)piperidin‐4‐yl]methyl Benzamides
Lindsley, C. W., Zhao, Z., Leister, W., O'Brien, J. L., Lemaire, W., Williams, D. L., Chen, T., Chang, R. S. L., Burno, M., Jacobson, M. A., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200600097 · Cited by 44
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction
Roberts, B. M., Holden, D., Shaffer, C. L., Seymour, P. A., Menniti, F. S., Schmidt, C. J., Williams, G. V., & Castner, S. A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.03.039 · Cited by 43
Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator
Spear, N., Gadient, R. A., Wilkins, D. E., Do, M., Smith, J. S., Zeller, K. L., Schroeder, P. E., Zhang, M., Arora, J., & Chhajlani, V. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.02.003 · Cited by 43
A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia
Reid, M. A., White, D. M., Kraguljac, N. V., & Lahti, A. C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.12.003 · Cited by 44
Cell-subtype-specific changes in adenosine pathways in schizophrenia
O'Donovan, S. M., Sullivan, C. R., Koene, R., Devine, E. A., Hasselfeld, K., Moody, C. L., & McCullumsmith, R. E. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0028-6 · Cited by 43
The effects of antipsychotic treatment on cerebral structure and function in schizophrenia
Vita, A., & Peri, L. M. D. (2007) · International Review of Psychiatry · doi:10.1080/09540260701486332 · Cited by 43
Disruption of hippocampal–prefrontal cortex activity by dopamine D2R-dependent LTD of NMDAR transmission
Banks, P. J., Burroughs, A. C., Barker, G. R. I., Brown, J. T., Warburton, E. C., & Bashir, Z. I. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512064112 · Cited by 42
Dysregulation of glutamate carboxypeptidase II in psychiatric disease
Guilarte, T. R., Hammoud, D. A., McGlothan, J. L., Caffo, B. S., Foss, C. A., Kozikowski, A. P., & Pomper, M. G. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.013 · Cited by 42
Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia
Pei, J.-C., Luo, D.-Z., Gau, S.-S., Chang, C., & Lai, W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.742058 · Cited by 48
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
de Bartolomeis, A., Vellucci, L., Austin, M. C., Simone, G. D., & Barone, A. (2022) · Biomolecules · doi:10.3390/biom12070909 · Cited by 43
Rolipram Attenuates MK-801-Induced Deficits in Latent Inhibition.
Davis, J. A., & Gould, T. J. (2005) · Behavioral Neuroscience · doi:10.1037/0735-7044.119.2.595 · Cited by 42
Science as a Way of Life: Perplexities of a Physician-Scientist
Bloom, F. E. (2003) · Science · doi:10.1126/science.1085535 · Cited by 42
The thalamus in psychosis spectrum disorder
Anticevic, A., & Halassa, M. M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1163600 · Cited by 47
Antioxidant Treatment in Male Mice Prevents Mitochondrial and Synaptic Changes in an NMDA Receptor Dysfunction Model of Schizophrenia
Phensy, A. J., Driskill, C. M., Lindquist, K. A., Guo, L., Jeevakumar, V., Fowler, B., Du, H., & Kroener, S. (2017) · eNeuro · doi:10.1523/eneuro.0081-17.2017 · Cited by 42
Immediate Early Genes Anchor a Biological Pathway of Proteins Required for Memory Formation, Long-Term Depression and Risk for Schizophrenia
Marballi, K. K., & Gallitano, A. L. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00023 · Cited by 42
NGL-2 Deletion Leads to Autistic-like Behaviors Responsive to NMDAR Modulation
Um, S. M., Ha, S., Lee, H., Kim, J., Kim, K., Shin, W., Cho, Y. S., Roh, J. D., Kang, J., Yoo, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.087 · Cited by 41
Auditory Mismatch Negativity Under Predictive Coding Framework and Its Role in Psychotic Disorders
Fong, C. Y., Law, W. H. C., Uka, T., & Koike, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.557932 · Cited by 48
Glutamate Receptor Subunits are Altered in Forebrain and Cerebellum in Rats Chronically Exposed to the NMDA Receptor Antagonist Phencyclidine
Lindahl, J. S., & Keifer, J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300485 · Cited by 41
Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis
Iasevoli, F., Polese, D., Ambesi-Impiombato, A., Muscettola, G., & de Bartolomeis, A. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.01.041 · Cited by 40
Prefrontal and Hippocampal Parvalbumin Interneurons in Animal Models for Schizophrenia: A Systematic Review and Meta-analysis
Santos‐Silva, T., Fabris, D. D. S., de Oliveira, C. L., Guimarães, F. S., & Gomes, F. V. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad123 · Cited by 45
NMDA receptor modulators: an updated patent review (2013 – 2014)
Strong, K. L., Jing, Y., Prosser, A. R., Traynelis, S. F., & Liotta, D. C. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.972938 · Cited by 43
A Whole-Brain and Cross-Diagnostic Perspective on Functional Brain Network Dysfunction
Spronk, M., Keane, B. P., Ito, T., Kulkarni, K. R., Ji, J. L., Anticevic, A., & Cole, M. W. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa242 · Cited by 43
The neuronal pathology of schizophrenia: molecules and mechanisms
Reynolds, G. P., & Harte, M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350433 · Cited by 40
Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions
Iasevoli, F., Fiore, G., Cicale, M., Muscettola, G., & de Bartolomeis, A. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.02.009 · Cited by 41
Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats
Callahan, P. M., Terry, A. V., & Tehim, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3509-2 · Cited by 39
Acute N-methyl-d-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats
Feinstein, I., & Kritzer, M. F. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.10.026 · Cited by 39
Elucidating the Role of Neurotensin in the Pathophysiology and Management of Major Mental Disorders
Boules, M., Fredrickson, P. A., Muehlmann, A. M., & Richelson, E. (2014) · Behavioral Sciences · doi:10.3390/bs4020125 · Cited by 42
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine
Hudson, M. R., Rind, G. S., O'Brien, T. J., & Jones, N. C. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.51 · Cited by 39
Backing into the future: pharmacological approaches to the management of resistant depression
Cowen, P. J. (2017) · Psychological Medicine · doi:10.1017/s003329171700068x · Cited by 39
Screening for modulators of neural network activity in 3D human iPSC-derived cortical spheroids
Woodruff, G., Phillips, N., Carromeu, C., Guicherit, O. M., White, A., Johnson, M., Zanella, F., Anson, B. D., Lovenberg, T. W., Bonaventure, P., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240991 · Cited by 40
Neurobiology of Schizophrenia Onset
Woo, T.-U. W. (2013) · Current topics in behavioral neurosciences · doi:10.1007/7854_2013_243 · Cited by 46
Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia
Haller, J., Szirmai, M., Varga, B., Ledent, C. A., & Freund, T. F. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00014 · Cited by 39
Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek, M. (2003) · PubMed · Cited by 39
Ketamine can produce oscillatory dynamics by engaging mechanisms dependent on the kinetics of NMDA receptors
Adam, E. M., Kowalski, M., Akeju, O., Miller, E. K., Brown, E. N., McCarthy, M. M., & Kopell, N. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402732121 · Cited by 37
Pharmacological Strategies for Enhancing Cognition in Schizophrenia
Barch, D. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_39 · Cited by 38
Cognitive impairments in poly-drug ketamine users
Liang, H. J., Lau, C. G., Tang, A., Chan, F., Ungvari, G. S., & Tang, W. K. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.06.017 · Cited by 40
A 1H-MR Spectroscopy Study of Changes in Glutamate and Glutamine (Glx) Concentrations in Frontal Spectra after Administration of Memantine
van Wageningen, H., Jørgensen, H. A., Specht, K., & Hugdahl, K. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhp145 · Cited by 38
Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders
Zhou, X., Nie, Z., Roberts, A. J., Zhang, D., Sebat, J. L., Malhotra, D., Kelsoe, J. R., & Geyer, M. A. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq298 · Cited by 38
Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells
Li, Q., Yan, H., Wilson, W. A., & Swartzwelder, H. S. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.029 · Cited by 38

Authors: Olney, J. W., Newcomer, J. W., & Farber, N. B.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Olney, John W
ORCID: Newcomer, John W
Farber, Nuri B
Venue: Journal of Psychiatric Research
Publisher: Elsevier BV
Published: 1999-11
Volume: 33
Issue: 6
Pages: 523-533
ISSN: 0022-3956 (ISSN-L)
DOI: 10.1016/s0022-3956(99)00029-1
OpenAlex: W2084120702
Cited by: 1,020
References: 63
Citations by year: 2026: 15 · 2025: 17 · 2024: 25 · 2023: 23 · 2022: 24 · 2021: 30 · 2020: 32 · 2019: 33 · 2018: 28 · 2017: 46 · 2016: 29 · 2015: 50 · 2014: 56 · 2013: 38 · 2012: 55
FWCI: 11.92
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Psychiatric Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5k02mh001510-05, 5k20da000290-05)
National Institute of Mental Health (MH33894, MH-01510)
National Institute on Drug Abuse (DA00290)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: schizophrenia, NMDA receptor hypofunction, phencyclidine, NMDA receptor antagonists, neurotoxicity, psychotomimetic effects, schizophrenia treatment
MeSH terms: Animals, Disease Models, Animal, Enzyme Inhibitors, Humans, Models, Biological, Models, Psychological, Phencyclidine, Schizophrenia, Receptors, N-Methyl-D-Aspartate, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NMDA receptor hypofunction model of schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks